Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics

Critical Reviews in Oncogenesis

Volumn 19, Issue 3-4, 2014, Pages 281-316

  Engelberth, Sarah A ^a   Hempel, Nadine ^a   Bergkvist, Magnus ^a  

^a SUNY POLYTECHNIC INSTITUTE   (United States)

Author keywords

Clinical trials; Gene therapy; Photodynamic therapy

Indexed keywords

DOXORUBICIN; LIPOSOME; NANOMATERIAL;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC IMAGING; DRUG FORMULATION; GYNECOLOGIC CANCER; HUMAN; LIPOSOMAL DELIVERY; NANOENCAPSULATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE RISK;

CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; LIPOSOMES; NANOTECHNOLOGY; OVARIAN NEOPLASMS;

EID: 84906086269     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2014011455     Document Type: Article

References (209)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stonach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719-725.
3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
4. Berns EM, Bowtell DD. Te changing view of high-grade serous ovarian cancer. Cancer Res. 2012;72:2701-2704.
5. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42:918-931.
6. Prat J. Ovarian carcinomas: five distinct diseases with diferent origins, genetic alterations, and clinicopathological features. Virchows Archiv. 2012;460:237-249.
7. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19:961-968.
8. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183-203.
9. Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003;90:491
10. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7:925-934.
11. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26:995-1005.
12. Davidson B. Ovarian carcinoma and serous efusions. changing views regarding tumor progression and review of current literature. Anal Cell Pathol. 2001;23:107-128.
13. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-1337.
14. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team. Efect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA: the journal of the American Medical Association. 2011;305:2295-2303.
15. Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? a review. Gynecol Oncol. 2011;120:152-157.
16. Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, Ruan Y, Ren S, Xu C, Gu J. Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res. 2013;12:4046-4055.
17. Li B, An HJ, Kirmiz C, Lebrilla CB, Lam KS, Miyamoto S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res. 2008;7:3776-3788.
18. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, Rudd PM. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology. 2007;17:1344-1356.
19. Biskup K, Braicu EI, Sehouli J, Fotopoulou C, Tauber R, Berger M, Blanchard V. Serum gly-come profling: a biomarker for diagnosis of ovarian cancer. J Proteome Res. 2013;12:4056-4063.
20. Nolen BM, Lokshin AE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ter. 2013;17:139-146.
21. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-46.
22. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heizelmann-Schwarz V. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121:487-491.
23. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC. The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49:521-525.
24. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the frst FDA-cleared in vitro diagnostic multivariate index assay of proteomic bio-markers. Cancer Epidemiol Biomarkers Prev. 2010;19:2995-2999.
25. Moore LE, Pfeifer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 2012;118:91-100.
26. Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, Pecora A, Suh KS. Early detection biomarkers for ovarian cancer. J Oncol. 2012;2012:709049.
27. Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc. 2008;130:10258-10262.
28. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gyencologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med. 2006;354:34-43.
29. Tewari D, Java J, Salari D, Armstrong M, Markman K, Herzog T, Monk B, Chan, J. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study (abstract GOG114/172). SGO Annual Meeting on Women's Cancer. Los Angeles. 2013.
30. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;CD005340.
31. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M. New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. BioMed Res Int. 2013;2013:852839.
32. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med. 2012;366:1382-1392.
33. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gersherson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14:134-140.
34. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283-290.
35. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl J Med. 2011;365:2473-2483.
36. Perren TJ, Swart AM, Pfsterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. New Engl J Med. 2011;365:2484-2496.
37. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of peme-trexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27:2686-2691.
38. Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer. 2009;45:1415-1423.
39. Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, Pecora A, Suh KS. Early detection biomarkers for ovarian cancer. J Oncol. 2012;2012:709049.
40. Kimmel DW, LeBlanc G, Meschievitz ME, Clifel DE. Electrochemical sensors and biosensors. Anal Chem. 2011;84:685-707.
41. Perfezou M, Turner A, Merkoci A. Cancer detection using nanoparticle-based sensors. Chem Soc Rev. 2012;41:2606-2622.
42. Swierczewska M, Liu G, Lee S, Chen X. High-sensitivity nanosensors for biomarker detection. Chem Soc Rev. 2012;41:2641-2655.
43. Bellan LM, Wu D, Langer RS. Current trends in nanobiosensor technology. Rev Nanomed Nanobiotechnol. 2011;3:229-246.
44. Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard AA, Simmons GW, Wong J, Gage C, Furmaga WB, Redding SW, McDevitt JT. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron. 2009;24:3622-3629.
45. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC Jr, McDevitt J T. Programmable bio-nano-chip systems for serum CA125 quan-tifcation: toward ovarian cancer diagnostics at the point-of-care. Cancer Prev Res (Phila). 2012;5:706-716.
46. Ravalli A, dos Santos GP, Ferroni M, Faglia G, Yamanaka H, Marrazza G. New label free CA125 detection based on gold nanostructured screen-printed electrode. Sens Actuators B. 2013;179:194-200.
47. Li J, Xu Q, Fu C, Zhang Y. A dramatically enhanced electrochemiluminescence assay for CA125 based on dendrimer multiply labeled luminol on Fe3O4 nanoparticles. Sens Actuators B. 2013;185:146-153.
48. Hong H, Zhang Y, Sun J, Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today. 2009;4:399-413.
49. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal Bioanal Chem. 2011;399:3-27.
50. Wu X, Wu M, Zhao JX. Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy. Nanomedicine. 2014;10:297-312.
51. Maldonado CR, Salassa L, Gomez-Blanco N, Mareque-Rivas JC. Nano-functionalization of metal complexes for molecular imaging and anticancer therapy. Coord Chem Rev. 2013;257:2668-2688.
52. Petersen AL, Hansen AE, Gabizon A, Andresen TL. Liposome imaging agents in personalized medicine. Adv Drug Deliv Rev. 2012;64:1417-1435.
53. Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med. 2010;16:561-573.
54. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052-1063.
55. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64:1394-1416.
56. Fleischer AC, Lyshchik A, Jones Jr. HW, Crispens M, Loveless M, Andreotti RF, Williams PK, Fishman DA. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: Preliminary fndings. J Ultrasound Med. 2008;27:1011-1018.
57. Fleischer AC, Lyshchik A, Andreotti RF, Hwang M, Jones HW, Fishman DA. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with micro-bubbles. Am J Roentgenol. 2010;194:343-348.
58. Wheatley MA, Lewandowski J. Nano-sized ultrasound contrast agent: salting-out method. Mol Imaging. 2010;9:96-107.
59. Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst. 2007;99:1095-1106.
60. Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KH. Controlled and targeted tumor chemotherapy by ultrasound-activated nano-emulsions/microbubbles. J Control Release. 2009;138:268-276.
61. Fleischer AC, Lyshchik A, Hirari M, Moore RD, Abramson RG, Fishman DA. Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements. J Oncol. 2012;2012:11.
62. Xu H, Regino CAS, Koyama Y, Hama Y, Gunn AJ, Bernardo M, Kobayashi H, Choyke PL, Brechbiel MW. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fuorescence imaging. Bioconj Chem. 2007;18:1474-1482.
63. Kamaly N, Kalber T, Tanou M, Bell JD, Miller AD. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconj Chem. 2009;20:648-655.
64. Wang L, Neoh KG, Kang E-T, Shuter B. Multifunctional polyglycerol-grafted Fe3O4@ SiO2 nanoparticles for targeting ovarian cancer cells. Biomaterials. 2011;32:2166-2173.
65. Zhou Z, Wang L, Chi X, Bao J, Yang L, Zhao W, Chen Z, Wang X, Chen X, Gao J. Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efcient tumor imaging. ACS Nano. 2013;7:3287-3296.
66. Misri R, Meier D, Yung AC, Kozlowski P, Häfeli UO. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe. Nanomedicine. 2012;8:1007-1016.
67. Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials. 2011;32:7127-7138.
68. Schädlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Göpferich A, Kuntsche J, Mäder K. Tumor accumulation of NIR fuorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano. 2011;5:8710-8720.
69. Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of paclitaxel and tanespimy-cin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS ONE. 2013;8:e58619.
70. Nathwani BB, Jafari M, Juriani AR, Mathur AB, Meissner KE. Fabrication and characterization of silk-fbroin-coated quantum dots. IEEE Trans NanoBiosci. 2009;8:72-77.
71. Wang H-Z, Wang H-Y, Liang R-Q, Ruan K-C. Detection of Tumor Marker CA125 in Ovarian Carcinoma Using Quantum Dots. Acta Biochimica et Biophysica Sinica. 2004;36:681-686.
72. Zdobnova TA, Dorofeev SG, Tananaev PN, Zlomanov VP, Stremovskiy OA, Lebedenko EN, Balalaeva IV, Deyev SM, Petrov RV. Imaging of human ovarian cancer SKOV-3 cells by quantum dot bioconjugates. Dokl Biochem Biophys. 2010;430:41-44.
73. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 2011;153:16-22.
74. Cassette E, Helle M, Bezdetnaya L, Marchal F, Dubertret B, Pons T. Design of new quantum dot materials for deep tissue infrared imaging. Adv Drug Deliv Rev. 2013;65:719-731.
75. Jokerst JV, Cole AJ, Van de Sompel D, Gambhir SS. Gold nanorods for ovarian cancer detection with photoacoustic imaging and resection guidance via raman imaging in living mice. ACS Nano. 2012;6:10366-10377.
76. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR efect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-284.
77. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987-992.
78. Muggia FM, Hainsworth JD, Jefers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modifcation by liposomal encapsulation. J Clin Oncol. 1997;15:987-993.
79. Gordon AN, Tonda M, Sun S, Rackof W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
80. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
81. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-2818.
82. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-896.
83. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588-591.
84. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauranine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-3114.
85. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ. Trabectedin plus peg ylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22:39-48.
86. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, Jacobs A, Curtin J, Muggia F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007;18:716-721.
87. Martin-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobi F, Alegre M, Goyenechea A, Pedreira J, Gonzalez del Castillo J, Martinez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, Gonzalez-Lahoz J; Caelyx/Kaposi's Sarcoma Spanish Group. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis. 2008;47:410-417.
88. Muggia F, Cannon T, Safra T, Curtin J. Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer. J Natl Cancer Inst. 2011;103:160-161.
89. Herzog TJ. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist. 2002;7 Suppl 5:3-10.
90. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and tar-getable nanoliposomal formulation of topotecan. J Control Release. 2010;141:13-21.
91. Dadashzadeh S, Vali AM, Rezaie M. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm. 2008;353:251-259.
92. Ma Y, Yang Q, Wang L, Zhou X, Zhao Y, Deng Y. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur J Pharm Sci. 2012;45:539-545.
93. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, Mcintosh L, Eisenhauer EA. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2005;23:1859-1866.
94. Corporation C. Abraxane.: Celgene Cor poration, Summit NY, Mirtsching B, Cosgrif T, Harker G, Keaton M, Chidiac T, Min M. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer. 2011;11:121-128.
95. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV 3rd. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol. 2006;100:437-438.
96. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper J T, Lentz SS, Hofman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:111-115.
97. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009;27:1426-1431.
98. Singer JW. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release. 2005;109:120-126.
99. Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA, Gynecologic Oncology Group S. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol. 2008;111:455-460.
100. Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ; Gynecologic Oncology Group. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008;110:329-335.
101. Hoch U ML, Maslyar D, Hoff D Von. NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer. Abstract 8015, ESMO 34 Conference, September 22 2009, 2:00 pm, Hall 141, Gynecologic Cancer, Poster Board 161. Nektar Terapeutics, San Carlos, CA
102. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013;14:1216-1225.
103. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011;34:27-31.
104. Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release. 2011;153:49-55.
105. Nowotnik DP, Cvitkovic E. ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev. 2009;61:1214-1219.
106. Duncan R. Development of HPMA copo-lymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009;61:1131-1148.
107. Lin X, Zhang Q, Rice JR, Stewart DR, Nowotnik DP, Howell SB. Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer. 2004;40:291-297.
108. Desale SS, Cohen SM, Zhao Y, Kabanov AV, Bronich TK. Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. J Control Release. 2013;171:339-348.
109. Gong C, Yang B, Qian Z, Zhao X, Wu Q, Qi X, Wang Y, Guo G, Kan B, Luo F, Wei Y. Improving intraperitoneal chemotherapeutic efect and preventing postsurgical adhesions simultaneously with biodegradable micelles. Nanomedicine. 2012;8:963-973.
110. Cho H, Lai TC, Kwon GS. Poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. J Control Release. 2013;166:1-9.
111. Kirkpatrick GJ, Plumb JA, Sutclife OB, Flint DJ, Wheate NJ. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem. 2011;105:1115-1122.
112. Kurtoglu YE, Mishra MK, Kannan S, Kannan RM. Drug release characteristics of PAMAM dendrimer-drug conjugates with diferent linkers. Int J Pharm. 2010;384:189-194.
113. Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxo-rubicin: the efects of PEGylation degree and drug conjugation style. Biomaterials. 2010;31:1360-1371.
114. Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2010;27:161-174.
115. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, Cheng RH, Wang L, Lam KS. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30:6006-6016.
116. Xiao W, Luo J, Jain T, Riggs JW, Tseng H P, Henderson PT, Cherry SR, Rowland D, Lam KS. Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformu-lation in a mouse xenograft model of ovarian cancer. Int J Nanomed. 2012;7:1587-1597.
117. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efcacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J. 2010;12:171-180.
118. Wagstaf AJ, Brown SD, Holden MR, Craig GE, Plumb JA, Brown RE, Schreiter N, Chrzanowski W, Wheate NJ. Cisplatin drug delivery using gold-coated iron oxide nanopar-ticles for enhanced tumour targeting with external magnetic felds. Inorg Chim Acta. 2012;393:328-333.
119. Qin Y, Song Q-G, Zhang Z-R, Liu J, Fu Y, He Q, Liu J. Ovarian tumor targeting of docetaxel-loaded liposomes mediated by lutein-izing hormone-releasing hormone analogues. Arzneimittelforschung. 2008;58:529-534.
120. Xiao K, Li Y, Lee JS, Gonik AM, Dong T, Fung G, Sanchez E, Xing L, Cheng HR, Luo J, Lam KS. "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 2012;72:2100-2110.
121. Nukolova NV, Oberoi HS, Cohen SM, Kabanov AV, Bronich TK. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials. 2011;32:5417-5426.
122. Nukolova NV, Oberoi HS, Zhao Y, Chekhonin VP, Kabanov AV, Bronich TK. LHRH-targeted nanogels as a delivery system for Cisplatin to ovarian cancer. Mol Pharm. 2013;10:3913-3921.
123. Gao ZG, Lee DH, Kim DI, Bae YH. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target. 2005;13:391-397.
124. Kim D, Lee ES, Park K, Kwon IC, Bae YH. Doxorubicin loaded pH-sensitive micelle: antitumoral efcacy against ovarian A2780/ DOXR tumor. Pharm Res. 2008;25:2074-2082.
125. Kim D, Gao ZG, Lee ES, Bae YH. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm. 2009;6:1353-1362.
126. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380-387.
127. Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T. Photodynamic therapy (PDT) for lung cancers. J Torac Oncol. 2006;1:489-493.
128. Allison RR, Sibata CH. Oncologic photody-namic therapy photosensitizers: a clinical review. Photodiagn Photodyn Ter. 2010;7:61-75.
129. Stolyarov AM, Wei L, Shapira O, Sorin F, Chua SL, Joannopoulos JD, Fink Y. Microfuidic directional emission control of an azimuth-ally polarized radial fbre laser. Nat Photon. 2012;6:229-233.
130. Davila ML. Photodynamic therapy. Gastrointest Endosc Clin N Am. 2011;21:67-79.
131. Master A, Livingston M, Sen Gupta A. Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release. 2013;168:88-102.
132. Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm. 2006;326:174-181.
133. Zeisser-Labouèbe M, Delie F, Gurny R, Lange N. Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases. Eur J Pharm Biopharma. 2009;71:207-213.
134. Li Z, Wang C, Cheng L, Gong H, Yin S, Gong Q, Li Y, Liu Z. PEG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted, NIR light induced, photodynamic therapy. Biomaterials. 2013;34:9160-9170.
135. Wang C, Tao H, Cheng L, Liu Z. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles. Biomaterials. 2011;32:6145-6154.
136. Cohen BA, Bergkvist M. Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids. J Photochem Photobiol B. 2013;121:67-74.
137. Mroz P, Xia Y, Asanuma D, Konopko A, Zhiyentayev T, Huang YY, Sharma SK, Dai T, Khan UJ, Wharton T, Hamblin MR. Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma. Nanomedicine. 2011;7:965-974.
138. Liu J, Ohta S, Sonoda A, Yamada M, Yamamoto M, Nitta N, Murata K, Tabata Y. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J Control Release. 2007;117:104-110.
139. Tabata Y, Murakami Y, Ikada Y. Photodynamic efect of polyethylene glycol-modifed fullerene on tumor. Jpn J Cancer Res. 1997;88:1108-1116.
140. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457-462.
141. Mansouri S, Cuie Y, Winnik F, Shi Q, Lavigne P, Benderdour M, Beaumont E, Fernandes JC. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials. 2006;27:2060-2065.
142. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173-184.
143. Heidel JD, Schluep T. Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv. 2012;2012:262731.
144. Reddy JA, Abburi C, Hofand H, Howard SJ, Vlahov I, Wils P, Leamon CP. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ter. 2002;9:1542-1550.
145. Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, Nunan R, Pirollo KF, Rait A, Chang EH. Phase I study of a systemi- cally delivered p53 nanoparticle in advanced solid tumors. Mol Ter. 2013;21:1096-1103.
146. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 2003;4:415-422.
147. Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DP, Harper P, Secki M, Tomas H, Lemoine NR, Charnock M, Habib NA, Lechler R, Nicholls J, Pignatelli M, Ganesan TS. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer over-expressing HER-2/neu oncogene. Clin Cancer Res. 2004;10:2986-2996.
148. Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2013;131:169-173.
149. Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012;4:147ra12.
150. Xie C, Gou ML, Yi T, Deng H, Li ZY, Liu P, Qi XR, He X, Wei Y, Zhao X. Efficient inhibition of ovarian cancer by truncation mutant of FILIP1L gene delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels. Human Gene Ter. 2011;22:1413-1422.
151. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
152. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406-417.
153. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011;17:1713-1721.
154. Sun C, Yi T, Song X, Li S, Qi X, Chen X, Lin H, He X, Li Z, Wei Y, Zhao X. Efcient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3. Oncol Rep. 2011;26:193-200.
155. Zou L, Song X, Yi T, Li S, Deng H, Chen X, Li Z, Bai Y, Zhong Q, Wei Y, Zhao X. Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor efects against ovarian cancer. Cancer Gene Ter. 2013;20:242-250.
156. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-defcient ovarian cancer cells. Proc Natl Acad Sci U S A. 2011;108:745-750.
157. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Terapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013;3:1302-1315.
158. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013;19:1806-1815.
159. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462-475.
160. Taker PH, Deavers M, Celestino J, Tornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145-5150.
161. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007;109:332-340.
162. Hasan N, Mann A, Ferrari M, Tanaka T. Mesoporous silicon particles for sustained gene silencing. Methods Mol Biol. 2013;1049:481-493.
163. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Research. 2010;70:3687-3696.
164. Dickerson EB, Blackburn WH, Smith MH, Kapa LB, Lyon LA, McDonald JF. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer. 2010;10:10.
165. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Tanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez- Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high- density lipoprotein nanoparticles. Neoplasia. 2011;13:309-319.
166. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E. Coadministration of a tumor-penetrating peptide enhances the efcacy of cancer drugs. Science. 2010;328:1031-1035.
167. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010;16:3910-3922.
168. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011;17:5674-5685.
169. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest. 2009;119:2231-2244.
170. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, Sempere LF, Conejo-Garcia JR. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012;72:1683-1693.
171. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Barter JF, Forst D, Rahman A. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol. 1989;160:812-817; discussion 817-9.
172. Gilmore D, Schulz M, Liu R, Zubris KA, Padera RF, Catalano PJ, Grinstaff MW, Colson YL. Cytoreductive surgery and intra-operative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma. Ann Surg Oncol. 2013;20:1684-1693.
173. Das M, Patil S, Bhargava N, Kang J-F, Riedel LM, Seal S, Hickman JJ. Auto-catalytic ceria nanoparticles ofer neuroprotection to adult rat spinal cord neurons. Biomaterials. 2007;28:1918-1925.
174. Heckert EG, Karakoti AS, Seal S, Self WT. Te role of cerium redox state in the SOD mimetic activity of nanoceria. Biomaterials. 2008;29:2705-2709.
175. Giri S, Karakoti A, Graham RP, Maguire JL, Reilly CM, Seal S, Rattan R, Shridhar V. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS ONE. 2013;8(1):e54578
176. Randall LM, Monk BJ. Bevacizumab toxici-ties and their management in ovarian cancer. Gynecol Oncol. 2010;117:497-504.
177. Lecarpentier E, Ouaf L, Mir O, Berveiller P, Maurel M, Pujade-Lauraine E, Bouillot JL, Veyrie N. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Invest New Drugs. 2011;29:1500-1503.
178. Bansal N, Hofman M. Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab. Gynecol Oncol. 2011;120:313-314.
179. Toraya-Brown S, Sheen MR, Baird JR, Barry S, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S. Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb). 2013;5:159-171.
180. Di Pasqua AJ, Yuan H, Chung Y, Kim JK, Huckle JE, Li C, Sadgrove M, Tran TH, Jay M, Lu X. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. J Nucl Med. 2013;54:111-116.
181. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfsch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm. 2010;7:775-785.
182. You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li C. Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: a platform for near-infrared light-trigged drug release. J Control Release. 2012;158:319-328.
183. Hun X, Zhang Z, Tiao L. Anti-Her-2 monoclonal antibody conjugated polymer fuorescent nanoparticles probe for ovarian cancer imaging. Anal Chim Acta. 2008;625:201-206.
184. Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G. Near-infrared fuorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond). 2013;8:875-890.
185. Dai Y, Ma PA, Cheng Z, Kang X, Zhang X, Hou Z, Li C, Yang D, Zhai X, Lin J. Up-Conversion Cell imaging and pH-induced thermally controlled drug release from NaYF4:Yb3+/Er3+@ hydrogel core-shell hybrid microspheres. ACS Nano. 2012;6:3327-3338.
186. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Teriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038-1044.
187. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res. 2004;10:3386-3395.
188. Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, Bridges AS, Kuijer JL, Napier ME, Zamboni WC, DeSimone JM. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of diferent sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine. 2013;9:686-693.
189. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovar Res. 2010;3:11.
190. Larson N, Yang J, Ray A, Cheney DL, Ghandehari H, Kopecek J. Biodegradable mul-tiblock poly(N-2-hydroxypropyl)methacryl-amide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. Int J Pharm. 2013;454:435-443.
191. Gao X, Wang B, Wei X, Men K, Zheng F, Zhou Y, Zheng Y, Gou M, Huang M, Guo G, Huang N, Qian Z, Wei Y. Anticancer efect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale. 2012;4:7021-7030.
192. Colson YL, Liu R, Southard EB, Schulz MD, Wade JE, Griset AP, Zubris KA, Padera RF, Grinstaf MW. Te performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis. Biomaterials. 2011;32:832-840.
193. Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kipparam J, Kulkarni A, Muto K, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, Bonventre JV, Mashelkar RA, Sengupta S. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efcacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A. 2012;109:11294-11299.
194. Perche F, Patel NR, Torchilin VP. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release. 2012;164:95-102.
195. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32:8548-8554.
196. Chaudhury A, Das S, Bunte RM, Chiu GN. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomed. 2012;7:739-751.
197. Kim D, Lee ES, Oh KT, Gao ZG, Bae YH. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small. 2008;4:2043-2050.
198. Zhang XY, Chen J, Zheng YF, Gao XL, Kang Y, Liu JC, Cheng MJ, Sun H, Xu CJ. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 2009;69:6506-6514.
199. Zhang X, Chen J, Kang Y, Hong S, Zheng Y, Sun H, Xu C. Targeted paclitaxel nanoparticles modifed with follicle-stimulating hormone beta 81-95 peptide show efective antitumor activity against ovarian carcinoma. Int J Pharm. 2013;453:498-505.
200. Winer I, Wang S, Lee Y-EK, Fan W, Gong Y, Burgos-Ojeda D, Spahlinger G, Kipelman R, Buckanovich RJ. F3-targeted cisplatin-hydrogel nanoparticles as an efective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 2010;70:8674-8683.
201. Zhao H, Wang J-C, Sun Q-S, Luo C-L, Zhang Q. RGD-based strategies for improving anti-tumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target. 2009;17:10-18.
202. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Diferential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int J Pharm. 2007;331:190-196.
203. Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immu-nonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci. 2009;38:230-237.
204. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. Beneft of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efcacy and biodistribution in mice. J Control Release. 2010;144:324-331.
205. Wang Y, Liu P, Qiu L, Sun Y, Zhu M, Gu L, Di W, Duan Y. Toxicity and therapy of cisplatin-loaded EGF modifed mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials. 2013;34:4068-4077.
206. Krieger ML, Eckstein N, Schneider V, Koch M, Royer H-D, Jaehde U, Bendas G. O vercoming cis-platin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm. 2010;389:10-17.
207. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ter. 1998;5:1538-1544.
208. Huang YH, Zugates GT, Peng W, Holtz D, Dunton C, Green JJ, Hossain N, Chernick MR, Padera RF Jr, Langer R, Anderson DG, Sawicki JA. Nanoparticle-delivered suicide gene therapy efectively reduces ovarian tumor burden in mice. Cancer Res. 2009;69:6184-6191.
209. Wang Y, Saad M, Pakunlu RI, Khandare JJ, Garbuzenko OB, Vetcher AA, Soldatenkov VA, Pozharov VP, Minko T. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clin Cancer Res. 2008;14:3607-3616.